39973-76-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-benzoyl-3-ethoxyacrylate is used as an intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the creation of complex molecular structures. Its reactivity allows for the development of new drugs with potential therapeutic benefits.
Used in Organic Chemistry:
As a reagent in organic chemistry, ethyl 2-benzoyl-3-ethoxyacrylate is employed in various chemical reactions to produce a wide range of organic compounds. Its versatility in synthesis contributes to the advancement of organic chemistry research and development.
Used in Fragrance and Flavoring Industry:
Ethyl 2-benzoyl-3-ethoxyacrylate is used as a key component in the production of fragrances and flavorings due to its unique chemical properties. It contributes to the development of new scents and tastes, enhancing the sensory experience of consumer products.
Used in Materials Science:
In the field of materials science, ethyl 2-benzoyl-3-ethoxyacrylate is utilized for its potential applications in creating novel materials with specific properties. Its reactivity allows for the development of materials with improved performance characteristics, such as enhanced strength, durability, or flexibility.
Used in Biotechnology:
Ethyl 2-benzoyl-3-ethoxyacrylate is employed in biotechnology for its potential use in the development of new biologically active compounds or as a component in bioprocesses. Its unique properties may contribute to the advancement of biotechnological applications, such as drug discovery or the production of biomaterials.

InChI:InChI=1/C14H16O4/c1-3-17-10-12(14(16)18-4-2)13(15)11-8-6-5-7-9-11/h5-10H,3-4H2,1-2H3/b12-10-

Upstream product

• 108-24-7 acetic anhydride 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 122-51-0 orthoformic acid triethyl ester 
• 7334-41-0 3-acetoxypropiophenone 

Downstream Products

• 100394-21-6 2-benzoyl-4-nitro-ξ-crotonic acid ethyl ester 
• 846549-50-6 5-cyano-2,6-diphenyl-nicotinic acid ethyl ester 
• 114954-07-3 ethyl 8-cyano-4,7-diphenylpyrrolo<1,2-a>pyrimidin-3-carboxylate 
• 86842-88-8 (4-Chloro-phenyl)-(9-ethyl-furo[2,3-b]indolizin-2-yl)-methanone 
• 114954-10-8 ethyl 8-cyano-1,4-dihydro-4,7-diphenylpyrrolo<1,2-a>pyrimidin-3-carboxylate 
• 854778-00-0 2-benzoyl-3-(2-trifluoromethyl-4-fluoro-phenylamino)-acrylic acid ethyl ester 
• 116344-31-1 ethyl 1-methyl-3-phenyl-1H-pyrazole-4-carboxylate 
• 854766-06-6 (4-{[{3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}(methyl)amino]methyl}phenyl)acetic acid 
• 854766-05-5 {4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl}acetic acid 
• 854778-03-3 methyl {4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl}acetate 

Relevant academic research and scientific papers

Toward Continuous-Flow Synthesis of Biologically Interesting Pyrazole Derivatives

A two-step continuous-flow synthesis of substituted pyrazole derivatives has been developed via the formation of vinylidene keto esters as key intermediates. Heterogeneous Ni2+-montmorillonite was found to be an efficient catalyst for orthoester condensation of 1,3-dicarbonyls under flow conditions. The intermediate reacted with methylhydrazine to afford pyrazole derivatives, for which suitable selection of a solvent played a key role in achieving high yields and excellent regioselectivities of the desired products. An application of this protocol has been demonstrated by the synthesis of a key intermediate for biologically active pyrazoles such as Bixafen. (Figure presented.).

QUINOLINE COMPOUNDS

To provide a novel LXRbeta agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A quinoline compound represented by the following general formula (1) or salt thereof, or their solvate

Diversity-oriented synthesis of 1-hydroxy-2,4-benzodioates by regioselective [3+3] cyclocondensations of 1,3-bis(silyloxy)-1,3-butadienes with 3-alkoxy- and 3-silyloxy-2-alkoxycarbonyl-2-en-1-ones

1-Hydroxy-3,5-dimethyl-2,4-benzodioates (4-hydroxyisophthalates) were prepared by [3+3] cyclocondensation of 1,3-bis(silyloxy)-1,3-butadienes with 3-ethoxycarbonyl-4-trimethylsilyloxy-3-penten-2-one which is synthesized from (symmetrical) ethyl 2-acetylacetoacetate. The [3+3] cyclization of 1,3-bis(silyloxy)-1,3-butadienes with 3-alkoxy-2-alkoxycarbonyl-2-en-1-ones, readily available by reaction of β-ketoesters with trialkyl orthoformiates, provide a convenient and regioselective approach to a great variety of 3-substituted 1-hydroxy-2,4-benzodioates that are not readily available by other methods.

MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is heterocycle or heteroaryl; J, Ja, E, F, G, Ma, M, Q, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS

Compounds of the formula and pharmaceutically acceptable salts thereof for use as inhibitors of cyclin dependent kinases, wherein: X is O, S(O)m; Y is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl; R1 is hydrogen or lower alkyl; R2 is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -O-alkyl, -O-aryl, -NR4R5; R3 is hydrogen or lower alkyl; R4 is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -O-alkyl, -O-aryl; R5 is hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, -O-alkyl, -O-aryl; and m is 0, 1 or 2. The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.